Please use this identifier to cite or link to this item: https://hdl.handle.net/1822/78969

TitlePrevalence of cognitive impairment before prostate cancer treatment
Author(s)Araújo, Natália
Costa, Adriana
Lopes, Catarina
Lopes-Conceição, Luisa
Ferreira, Augusto
Carneiro, Filipa
Oliveira, Jorge
Morais, Samantha
Figueiredo, Luís Pacheco
Ruano, Luis
Cruz, Vítor Tedim
Pereira, Susana
Lunet, Nuno
KeywordsProstate cancer
Prevalence study
Cognitive dysfunction/epidemiology
Neuropsychological test
cognitive dysfunction
epidemiology
Issue date7-Mar-2022
PublisherMultidisciplinary Digital Publishing Institute (MDPI)
JournalCancers
CitationAraújo, N.; Costa, A.; Lopes, C.; Lopes-Conceição, L.; Ferreira, A.; Carneiro, F.; Oliveira, J.; Morais, S.; Pacheco-Figueiredo, L.; Ruano, L.; Tedim Cruz, V.; Pereira, S.; Lunet, N. Prevalence of Cognitive Impairment before Prostate Cancer Treatment. Cancers 2022, 14, 1355. https://doi.org/10.3390/cancers14051355
Abstract(s)Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa treatment. Between February 2018 and April 2021, the NEON-PC cohort recruited 605 patients with PCa proposed for treatment at the Portuguese Institute of Oncology of Porto. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive performance. Participants with a MoCA < 1.5 standard deviations (SD) of age- and education-specific normative values were considered to have probable cognitive impairment (PCI) and were referred for a comprehensive neuropsychological assessment. Data from the population-based cohort EPIPorto (<i>n</i> = 351 men aged ≥40 years, evaluated in 2013–2015) were used for comparison. The prevalence of PCI was 17.4% in EPIPorto and 14.7% in NEON-PC (age- and education-adjusted odds ratio: 0.82, 95%CI: 0.58,1.18). Neuropsychological assessment was performed in 63 patients with PCa: 54.0% had cognitive impairment. These results suggest that the impact of PCa on cognitive performance could be negligible in the short term, contrary to what other studies have reported regarding other types of cancer.
TypeArticle
URIhttps://hdl.handle.net/1822/78969
DOI10.3390/cancers14051355
e-ISSN2072-6694
Publisher versionhttps://www.mdpi.com/2072-6694/14/5/1355
Peer-Reviewedyes
AccessOpen access
Appears in Collections:BUM - MDPI

Files in This Item:
File Description SizeFormat 
cancers-14-01355.pdf475,47 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID